Get the Stockscreener App
1.37
1.44%
-0.02
After Hours:
1.34
-0.03
-2.19%
Celularity Inc stock is traded at $1.37, with a volume of 19,256.
It is down -1.44% in the last 24 hours and up +13.22% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$1.39
Open:
$1.45
24h Volume:
19,256
Relative Volume:
0.13
Market Cap:
$39.51M
Revenue:
$40.58M
Net Income/Loss:
$-80.65M
P/E Ratio:
-0.4113
EPS:
-3.331
Net Cash Flow:
$-8.11M
1W Performance:
+4.58%
1M Performance:
+13.22%
6M Performance:
-36.28%
1Y Performance:
-7.43%
1-Day Range:
$1.37
$1.45
1-Week Range:
$1.29
$1.45
52-Week Range:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.37 | 40.08M | 40.58M | -80.65M | -8.11M | -3.331 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey - Defense World
Exclusive: NexGel to acquire regenerative biomaterial portfolio from Celularity, expects to triple revenue - MSN
Barach Family Trust Secures Board Observer Role at Celularity with 9.56% Stake - TradingView
Barach Family Trust backs Celularity (CELU) with $10M notes and 9.56% stake - Stock Titan
Celularity Inc. (CELU) stock price, news, quote and history - Yahoo Finance UK
Celularity Delays Annual 10-K Filing Amid Strains - TipRanks
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity - marketscreener.com
NEXGEL delays earnings call a week to add detail on Celularity deal - Stock Titan
Market Review: Can Celularity Inc outperform in the next rallyTrade Risk Report & Expert Approved Momentum Ideas - baoquankhu1.vn
NEXGEL to pay $15 million for Celularity regenerative biomaterial portfolio - msn.com
Aug Analyst Calls: Is Celularity Inc Equity Warrant forming higher highs and higher lows2026 Major Catalysts & Fast Moving Trade Plans - baoquankhu1.vn
Death Cross: Why is Celularity Inc stock going upWeekly Market Report & Entry Point Strategy Guides - baoquankhu1.vn
Portfolio Update: Is Celularity Inc Equity Warrant a top pick in the sector2026 Fundamental Recap & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Update Recap: Will Celularity Inc Equity Warrant benefit from AI trendsQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Fund Flows: Can Celularity Inc stock outperform in a bear marketEarnings Recap Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Gains Report: Is Celularity Inc a stock for growth or value investors - baoquankhu1.vn
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Growth Review: Can Celularity Inc sustain earnings growthMarket Movement Recap & Low Risk High Reward Ideas - baoquankhu1.vn
If You Invested $1,000 in Celularity Inc (CELU) - Stock Titan
Aug Summary: Can Celularity Inc maintain sales growth2026 Drop Watch & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Breakout Move: Can Celularity Inc outperform in the next rally2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Bond Watch: What is Celularity Inc Equity Warrants revenue forecastM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
NEXGEL to Pay $15 Million for Celularity Regenerative Biomaterial Portfolio - MyChesCo
Stock Report: Will Celularity Inc Equity Warrant benefit from AI trends2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Targets Report: Will Celularity Inc benefit from government policy2026 AllTime Highs & Long-Term Safe Investment Ideas - baoquankhu1.vn
Celularity strikes up to $35M licensing deal for biomaterials portfolio - MSN
WBB Securities Upgrades Celularity (CELU) - MSN
CelularityFinancial Details - Crunchbase
Buyback Watch: What is Celularity Inc Equity Warrants revenue forecast2026 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
NEXGEL discloses $15M upfront payment for Celularity portfolio By Investing.com - Investing.com Canada
Celularity inks $35m deal for longevity push - Longevity.Technology
NXGL Stock: NEXGEL Signs Deal to Triple Revenue and Turn Profitable With Acquisition of Six Commercial-Stage Regenerative Biomaterial Products - Barchart.com
NEXGEL discloses $15M upfront payment for Celularity portfolio - Investing.com
NEXGEL Announces $15 Million Acquisition of Regenerative Biomaterial Products from Celularity, Expected to Triple Revenue and Drive Profitability - Quiver Quantitative
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - The Manila Times
Biomaterial deal aims to triple NEXGEL sales and turn profit - Stock Titan
Inside Celularity’s bet on NEXGEL to shake up wound care biomaterials - Stock Titan
Biotechnology company Celularity Inc. (NASDAQ: CELU) recently reaffirmed its strategic commercialization partnership with NEXGEL, INC. (NASDAQ: NXGL). - Bitget
Macro Review: Is Celularity Inc Equity Warrant a speculative investmentIndex Update & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Celularity licenses biomaterials portfolio for up to $35 million By Investing.com - Investing.com Canada
Celularity licenses biomaterials portfolio for up to $35 million - Investing.com Nigeria
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - Investing News Network
Celularity Inc. Secures $35 Million Strategic License Deal and Strengthens Capital Position to Advance Longevity-Focused Strategy - marketscreener.com
NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal - TipRanks
Celularity Licenses Biomaterials Portfolio to NexGel Partner - TipRanks
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):